Treatment
Various approaches have been identified for treating borderline personality disorder. Psychotherapy has been propagated as the primary treatment option with pharmacotherapy presented as a supplement segment of the treatment that focuses on the observed symptoms during the occurrence of the problem (Leichsenring et al., 2011).
Pharmacotherapy
Pharmacological approaches to BPD can be classified into for groups: antidepressants, mood stabilizers, antipsychotics and hypnotics/benzodiazepines. The extent to which these agents are applied are varied depending on many factors such as the nature of symptoms present and the severity of BPD, and the magnitude of comorbidities. Evidence has indicated that 30-80% of individuals affected by BDP use antidepressants, 30 -85% benzodiazepines 20-70 use mood stabilizers and 33-77percent use antipsychotics (Paton et al., 2015). Contrary to expectations massive use of pharmacotherapy in borderline personality disorder has not been shown to conclusively show positive outcomes. As a result there have been strong debates regarding the efficacy of pharmacotherapy in addressing BPD. Paton et al., 2015). Francois et al., (2015) pointed out that the effectiveness of pharmacological agents is mixed. They point out that these disparities may arise from inconsistent or issues with clinical trials thereby generating variable results.
The American
Psychiatric Association has provided various guidelines regarding the applications of these drugs. One such recommendation its that they should be used are a targeted strategy whereby particular drugs may be produce better outcomes for specific symptoms of borderline personality disorder. For instance, selective serotonin reuptake inhibitors (SSRIs) have been shown to function well for dysregulation symptoms including rejection uninhibited anger, mood swings and episodic temper, and impulsive-behavioral instabilities including physical self-injury and episodic aggression.
Targeted symptom-based approaches of treating BPD
has not received substantial backing for empirical research. Consequently, there have been frequent reviews of targeted pharmacological agents for specific symptoms.
Methodological basis has been purported as the major obstacle to thse approaches and has led to polypharamcy, a tendency the attribute a particular drug to particular BPD symptoms. To date, a combination of omega-3 fatty acids and valproate has been gaidn significant support in curtailing the severity of borderline personality disorder and alleviating many associated symptoms.
In the long run health experts make use pharmacotherapy as a last resort when either sufficient psychotherapy is not available or when there is an acute surge of exacerbation during psychotherapy.
In both of these cases, clinicians usually give education when they observe aggression, self harm, depression or psychotic tendencies among the patients.
In some cases borderline personality disorder can be erroneously be diagnosed as bipolar disorder a situation which may prompt the use of pharmacological agents (Francois et al., 2015). Treatment
There are various approaches that have been identified for treating borderline personality disorder. Psychotherapy has been propagated as the main treatment option with pharmacotherapy presented as a supplement segment of the treatment that focuses on the observed symptoms during the occurrence of the problem (Leichsenring et al., 2011).
Pharmacotherapy
Pharmacological approaches to BPD can be classified into for groups: antidepressants, mood stabilizers, antipsychotics and hypnotics/benzodiazepines. The extent to which these agents are applied are varied depending on many factors such as the nature of symptoms present and the severity of BPD, and the magnitude of comorbidities. Evidence has indicated that 30-80% of individuals affected by BDP use antidepressants, 30 -85% benzodiazepines 20-70 use mood stabilizers and 33-77percent use antipsychotics (Paton et al., 2015). Contrary to expectations massive use of pharmacotherapy in borderline personality disorder has not been shown to conclusively show positive outcomes. As a result there have been strong debates regarding the efficacy of pharmacotherapy in addressing BPD. Paton et al., 2015). Francois et al., (2015) pointed out that the effectiveness of pharmacological agents is mixed. They point out that these disparities may arise from inconsistent or issues with clinical trials thereby generating variable results.
The American
Psychiatric Association has provided various guidelines regarding the applications of these drugs. One such recommendation its that they should be used are a targeted strategy whereby particular drugs may be produce better outcomes for specific symptoms of borderline personality disorder. For instance, selective serotonin reuptake inhibitors (SSRIs) have been shown to function well for dysregulation symptoms including rejection uninhibited anger, mood swings and episodic temper, and impulsive-behavioral instabilities including physical self-injury and episodic aggression.
Targeted symptom-based approaches of treating BPD
has not received substantial backing for empirical research. Consequently, there have been frequent reviews of targeted pharmacological agents for specific symptoms.
Methodological basis has been purported as the major obstacle to thse approaches and has led to polypharamcy, a tendency the attribute a particular drug to particular BPD symptoms. To date, a combination of omega-3 fatty acids and valproate has been gaidn significant support in curtailing the severity of borderline personality disorder and alleviating many associated symptoms.
In the long run health experts make use pharmacotherapy as a last resort when either sufficient psychotherapy is not available or when there is an acute surge of exacerbation during psychotherapy.
In both of these cases, clinicians usually give education when they observe aggression, self harm, depression or psychotic tendencies among the patients.
In some cases borderline personality disorder can be erroneously be diagnosed as bipolar disorder a situation which may prompt the use of pharmacological agents (Francois et al., 2015).